Abstract
Application of viral vectors derived from human viruses to mediate immune response in animals and humans has been greatly hampered by the problems associated with pre-existing immunity and associated toxicities. Among few non-human viral vectors, baculovirus has now evolved as a novel tool for vaccine vector development. With broad tissue tropism and expanded bio-safety profile suitably supplemented with intrinsic immunostimulatory properties, baculovirus has now attained a niche position in the arena of vaccine development. Recombinant envelope-modified baculovirus equipped with novel shuttle promoters for in vivo transduction has shown promising results in several animal models. Baculovirus mediated induction of systemic and mucosal immune responses through intranasal or oral administration has now opened an entirely new way for the development of new generation vaccines. Gaining additional insight into the baculovirus biology and its interaction with non-native hosts will certainly promote this human-friendly virus as a potential vector for clinical applications.
Keywords: Non-human viral vector, recombinant baculovirus, gene-delivery, vaccine, innate immunity, infectious diseases
Current Gene Therapy
Title: Baculovirus as Vaccine Vectors
Volume: 10 Issue: 3
Author(s): Selvaraj Madhan, Mookkan Prabakaran and Jimmy Kwang
Affiliation:
Keywords: Non-human viral vector, recombinant baculovirus, gene-delivery, vaccine, innate immunity, infectious diseases
Abstract: Application of viral vectors derived from human viruses to mediate immune response in animals and humans has been greatly hampered by the problems associated with pre-existing immunity and associated toxicities. Among few non-human viral vectors, baculovirus has now evolved as a novel tool for vaccine vector development. With broad tissue tropism and expanded bio-safety profile suitably supplemented with intrinsic immunostimulatory properties, baculovirus has now attained a niche position in the arena of vaccine development. Recombinant envelope-modified baculovirus equipped with novel shuttle promoters for in vivo transduction has shown promising results in several animal models. Baculovirus mediated induction of systemic and mucosal immune responses through intranasal or oral administration has now opened an entirely new way for the development of new generation vaccines. Gaining additional insight into the baculovirus biology and its interaction with non-native hosts will certainly promote this human-friendly virus as a potential vector for clinical applications.
Export Options
About this article
Cite this article as:
Madhan Selvaraj, Prabakaran Mookkan and Kwang Jimmy, Baculovirus as Vaccine Vectors, Current Gene Therapy 2010; 10 (3) . https://dx.doi.org/10.2174/156652310791321233
DOI https://dx.doi.org/10.2174/156652310791321233 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cratylia mollis Lectin: A Versatile Tool for Biomedical Studies
Current Bioactive Compounds Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Crocetin as an Active Secondary Metabolite of Saffron Stigma and Anticancer Effects
Current Cancer Therapy Reviews Association of Gag Multimers with Filamentous Actin During Equine Infectious Anemia Virus Assembly
Current HIV Research Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry High-Throughput Techniques for Identifying microRNA Target Genes
Current Bioinformatics Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy HIV and Respiratory Disease: A Contemporary Perspective
Current Respiratory Medicine Reviews Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Anal Cancer: Focus on HIV-Positive Patients in the HAART Era
Current HIV Research Therapeutic AIDS Vaccines
Current Pharmaceutical Design The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer
Current Pharmaceutical Design Mechanism of Action and Therapeutic Potential of Novel Adamantyl Retinoid-Related Molecules
Current Cancer Therapy Reviews Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Anticancer Natural Coumarins as Lead Compounds for the Discovery of New Drugs
Current Topics in Medicinal Chemistry NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine